KELLY POLUS: Open Payments
NPI 1689770919 · MISSOULA, MT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$874 in 49 payments from 11 companies in 2025. Trend: 2023 $330 · 2024 $565 · 2025 $874
Food & beverage: $867Education: $7
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $280 |
| Vanda Pharmaceuticals Inc. | 19 | $222 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $90 |
| Lilly USA, LLC | 3 | $58 |
| Boston Scientific Corporation | 1 | $56 |
| AstraZeneca Pharmaceuticals LP | 3 | $43 |
| SI-BONE, INC. | 1 | $36 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| Gilead Sciences, Inc. | 1 | $25 |
| PFIZER INC. | 1 | $16 |
Products named: FANAPT, QULIPTA, CAPLYTA, UBRELVY, VRAYLAR, WATCHMAN FLX, AIRSUPRA, MOUNJARO.
Industry payments across MT — which companies pay providers there.
